Next-Generation Sequencing Analysis of Circulating Tumor DNA

Oliver Zill
Published: Monday, Sep 26, 2016



Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

In the analysis, it was also found that the positive predictive value for finding actionable variance is high across key biomarkers, Zill explains. Researchers are also detecting actionable emerging resistance via circulating tumor DNA, which usually emerges after a patient undergoes a biopsy.


Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

In the analysis, it was also found that the positive predictive value for finding actionable variance is high across key biomarkers, Zill explains. Researchers are also detecting actionable emerging resistance via circulating tumor DNA, which usually emerges after a patient undergoes a biopsy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x